Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation

Transplantation

Volumn 97, Issue 7, 2014, Pages 775-780

  Stifft, Frank ^a   Stolk, Leo M L ^a   Undre, Nasrullah ^b   Van Hooff, Johannes P ^a   Christiaans, Maarten H L ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

Author keywords

Drug exposure; Formulation; Intra patient coefficient of variability; Pharmacokinetics; Tacrolimus; Therapeutic drug monitoring

Indexed keywords

CYTOCHROME P450 3A5; MYCOPHENOLIC ACID; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ADULT; AFRICAN AMERICAN; AGED; AREA UNDER THE CURVE; ARTICLE; CHINESE; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRIED BLOOD SPOT TESTING; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG FORMULATION; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GLOMERULUS FILTRATION RATE; HOMOZYGOSITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAINDIVIDUAL VARIABILITY; KIDNEY TRANSPLANTATION; MALE; PATIENT COMPLIANCE; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; CHEMISTRY, PHARMACEUTICAL; CYTOCHROME P-450 CYP3A; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; TACROLIMUS;

EID: 84897568236     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000437561.31212.0e     Document Type: Article

References (18)

1. Alloway R, Steinberg S, Khalil K, et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc 2005; 37: 867.
2. van Hooff J, Van der Walt I, Kallmeyer J, et al. Pharmacokinetics in stable kidney transplant recipients after conversion from twicedaily to once-daily tacrolimus formulations. Ther Drug Monit 2012; 34: 46.
3. Budde K, Glander P. Pharmacokinetic principles of immunosuppressive drugs. Ann Transplant 2008; 13: 5.
4. Florman S, Alloway R, Kalayoglu M, et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc 2005; 37: 1211.
5. Borra LC, Roodnat JI, Kal JA, et al. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant 2010; 25: 2757.
6. Kuypers DR, Peeters PC, Sennesael JJ, et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation 2013; 95:333.
7. Wu MJ, Cheng CY, Chen CH, et al. Lower variability of tacrolimus trough concentration after conversion from Prograf to Advagraf in stable kidney transplant recipients. Transplantation 2011; 92: 648.
8. Cheung CY, Op den Buijsch RA, Wong KM, et al. Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients. Pharmacogenomics 2006; 7: 563.
9. Lee SJ, Usmani KA, Chanas B, et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 2003; 13: 461.
10. van Schaik RH, van der Heiden IP, van den Anker JN, et al. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002; 48: 1668.
11. Hoogtanders K, van der Heijden J, Christiaans M, et al. Therapeutic drug monitoring of tacrolimus with the dried blood spot method. J Pharm Biomed Anal 2007; 44: 658.
12. Wlodarczyk Z, Squifflet JP, Ostrowski M, et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant 2009; 9: 2505.
13. Yong Chung J, Jung Lee Y, Bok Jang S, et al. CYP3A5*3 genotype associated with intrasubject pharmacokinetic variation toward tacrolimus in bioequivalence study. Ther Drug Monit 2010; 32: 67.
14. Pashaee N, Bouamar R, Hesselink DA, et al. CYP3A5 genotype is not related to the intrapatient variability of tacrolimus clearance. Ther Drug Monit 2011; 33: 369.
15. Op den Buijsch RA, van de Plas A, Stolk LM, et al. Evaluation of limited sampling strategies for tacrolimus. Eur J Clin Pharmacol 2007; 63: 1039.
16. Cheung CY, van der Heijden J, Hoogtanders K, et al. Dried blood spot measurement: application in tacrolimus monitoring using limited sampling strategy and abbreviated AUC estimation. Transpl Int 2008; 21: 140.
17. Hoogtanders K, van der Heijden J, Christiaans M, et al. Dried blood spot measurement of tacrolimus is promising for patient monitoring. Transplantation 2007; 83: 237.
18. In: Agency EM, ed. Note for Guidance on the Investigation of Bioavailability and Bioequivalence (NfG on BA/ BE). London; 2010.